These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 446311)

  • 41. Factors influencing comparative bioavailability of spironolactone tablets.
    Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
    J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The bio-availability of beta-acetyldigoxine (Novodigal) alone and combined with oxyfedrine (Ildamen-Novodigal).
    Bonelli J; Hruby K; Magometschnigg D; Hitzenberger G; Kaik G
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):288-93. PubMed ID: 881282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of food intake on antihypertensive drugs: spironolactone.
    Thulin T; Wåhlin-Boll E; Liedholm H; Lindholm L; Melander A
    Drug Nutr Interact; 1983; 2(3):169-73. PubMed ID: 6678756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
    van der Merwe PJ; Müller DG; Clark EC
    J Chromatogr; 1979 Apr; 171():519-21. PubMed ID: 546864
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of spironolactone treatment on the renin-aldosterone system during pregnancy.
    Lammintausta R; Erkkola R
    Int J Clin Pharmacol Biopharm; 1979 Jul; 17(7):294-8. PubMed ID: 489194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.
    Karim A; Hribar J; Aksamit W; Doherty M; Chinn LJ
    Drug Metab Dispos; 1975; 3(6):467-78. PubMed ID: 1221
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of food on the bioavailability of spironolactone.
    Overdiek HW; Merkus FW
    Clin Pharmacol Ther; 1986 Nov; 40(5):531-6. PubMed ID: 3769384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The metabolism and biopharmaceutics of spironolactone in man.
    Overdiek HW; Merkus FW
    Rev Drug Metab Drug Interact; 1987; 5(4):273-302. PubMed ID: 3333882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
    Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
    J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Smithurst BA
    Eur J Clin Pharmacol; 1984; 27(4):435-9. PubMed ID: 6519150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
    Abosehmah-Albidy AZ; York P; Wong V; Losowsky MS; Chrystyn H
    Br J Clin Pharmacol; 1997 Jul; 44(1):35-9. PubMed ID: 9241094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of spironolactone metabolites in plasma and target organs of guinea pigs.
    Los LE; Coddington AB; Ramjit HG; Colby HD
    Drug Metab Dispos; 1993; 21(6):1086-90. PubMed ID: 7905388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spironolactone metabolism in normal subjects and in patients with liver cirrhosis.
    Váradi A; Fehér T; Bodrogi L; Koref O
    Arzneimittelforschung; 1977; 27(8):1618-20. PubMed ID: 578759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Studies on the bioavailability of the individual components from a combination of dilazep and beta-acetyldigoxin (author's transl)].
    Schaumlöffel E; Prignitz R
    Arzneimittelforschung; 1976; 26(12):2208-13. PubMed ID: 1037278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative bioavailability of Verospiron and Aldactone tablets in humans.
    János C; László V; Sándor KF; Zsolt S; Gabor R
    Acta Pharm Hung; 1982 Nov; 52(6):274-79. PubMed ID: 7158363
    [No Abstract]   [Full Text] [Related]  

  • 58. Improved bioavailability from a spironolactone beta-cyclodextrin complex.
    Yusuff NT; York P; Chrystyn H; Bramley PN; Swallow RD; Tuladhar BR; Losowsky MS
    Eur J Clin Pharmacol; 1991; 40(5):507-11. PubMed ID: 1884726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk.
    Phelps DL; Karim A
    J Pharm Sci; 1977 Aug; 66(8):1203. PubMed ID: 894512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of single and divided daily dose spironolactone in the control of hypertension.
    Bell GM; Fananapazir L; Anderton JL
    Br J Clin Pharmacol; 1981 Oct; 12(4):585-8. PubMed ID: 7295494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.